The author recounts their experience with embryo selection technology while navigating the IVF process to have children. They learned about a startup named Herasight, which claims to provide predictions about disease risk and IQ based on embryo analysis. Despite the technology's limitations—certain traits being poorly predicted and a significant financial commitment of about $26,000 for two cycles—the couple opted to pursue this route. They believed that even weak signals across multiple traits could yield meaningful benefits and wanted to support the advancement of the technology for future parents. Trust played a key role in their decision-making. They spoke with Herasight's team, assessed their research, and relied on recommendations from friends in genetics to validate the company's credibility. The couple's calculations suggested that the potential reduction in disease risk made the investment worthwhile, leading them to proceed despite uncertainties. The IVF process itself was demanding, with two rounds of egg extraction resulting in eight viable embryos. Ultimately, the couple used a spreadsheet to weigh the predicted traits of each embryo, considering health risks and capabilities. They negotiated their differing priorities, averaging their individual assessments to create a final ranking of the embryos. The one with the best score was implanted, leading to the birth of their son. Throughout the process, the author reflects on the emotional stakes and the complexities of selecting embryos based on genetic predictions, particularly regarding concerns like Alzheimer’s disease that deeply affected them.